Niva Bupa Health Insurance IPO
Niva Bupa Health Insurance Company Ltd
₹14,000 /200 sharesMinimum Investment
Niva Bupa Health Insurance IPO Listing Details
Listed On | Issue Price | Listing Price | Listing Gains |
---|
-- | ₹74.00 | ₹78.14 | ₹4.14 (5.59%) |
Niva Bupa Health Insurance IPO Details
Bidding Dates | Min. Investment | Lot Size | Price Range |
---|
7 Nov ‘24 - 11 Nov ‘24 | ₹14,000 | 200 | ₹70 - ₹74 |
Issue Size | IPO Doc |
---|
2200.00Cr | |
Qualified Institutional Buyers | 1.90x |
Non-Institutional Investor | 0.66x |
Retail Individual Investor | 2.56x |
Total | 1.68x |
Niva Bupa Health Insurance Company Limited is promoted by Bupa Singapore Holdings Pte. Ltd. and Bupa Investments Overseas Limited, members of the Bupa Group. This makes Niva Bupa Health Insurance Company Limited the only health insurance company in India to be majority controlled by a foreign global healthcare group. Niva Bupa Health Insurance Company’s association with these foreign players gives it access to their international healthcare insurance experience.
Established in 1947, the Bupa Group is an international healthcare organisation serving over 50 million customers globally as of December 31, 2023. The Bupa Group offers health insurance, healthcare provision, and aged services around the world, but principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong SAR, Türkiye, Brazil, Mexico, India, the US, the Middle East, and Ireland. Bupa also has an associate business in Saudi Arabia.
The company had 14.73 million active lives insured as of March 31, 2024. It claims to be strategically focused on the retail health market, with gross written premium (GWP) from its retail health products at 68.47% of its overall GWP for the financial year 2023-24.;
Managing director
Mr. Krishnan Ramachandran
Parent organisation
Niva Bupa Health Insurance Company Ltd
Strengths & Financials of Niva Bupa Health Insurance
The company claims to be the third-largest and second-fastest-growing standalone health insurer (SAHI) in India based on overall health gross direct premium income (GDPI) in FY24, at a compounded annual growth rate (CAGR) of 41.37% from FY22 to FY24.
The company claims to have a market share in the Indian SAHI market of 16.24%, 15.58%, and 13.87% for financial years 2024, 2023, and 2022 based on retail health GDPI.
The company’s diverse distribution channels, including direct sales through its website and other digital-related distributors, have contributed to its growth in GWP and improved its operating leverage, while lowering the expenses of management as a percentage of GWP to 39.29% in FY24, 41.14% in FY23, from 42.46% in FY22.
The company has put in place automated and digital self-service capabilities aimed at enabling customers to benefit from a seamless experience with minimal manual intervention. For FY24, it had 99.95% of its new policies applied for digitally, 81.27% of the claims submitted digitally, 85.39% of renewals completed without human intervention, and 95.50% of the number of payments received made digitally through its website and mobile app.
The company’s profitability depends on its ability to manage its underwriting risks and appropriately price its products. Any failure to accurately estimate medical expenses or the frequency of claims could have a material adverse effect on its business, financial condition, results of operations, cash flows, and business prospects.
Pandemics like COVID-19 or other major negative events could hurt the company’s financials in a big way.
A significant portion of the company’s business is generated from health insurance. Any adverse trends and other developments in this area could negatively affect the sale of the company’s health insurance products.
The company depends on network hospitals to offer the cashless claims settlement option to its customers and manage its claims costs through the negotiation of certain tariffs. In case of any failure to develop and maintain satisfactory relationships with the network hospitals, the company’s ability to offer cashless claims to its customers and effectively manage its claims costs may be adversely affected.
Any failure by the company to pay claims accurately and on time could lead to customer dissatisfaction and result in regulatory actions or penalties, which could hurt its business.
The company incurred a loss of Rs 196.52 crore in FY22. Any losses in future could adversely impact the company’s business prospects.
The actuarial valuations of liabilities for the company’s policies with outstanding liabilities are certified by the appointed actuary, and if such valuation is incorrect, it could adversely impact the company’s financial condition.
Niva Bupa Health Insurance Financials
*All values are in Rs. Cr
Application Details of Niva Bupa Health Insurance IPO
Apply as | Price band | Apply upto |
---|
Regular | ₹70 - 74 | ₹2 Lakh |
High Networth Individual | ₹70 - 74 | ₹2 - 5 Lakh |
For Niva Bupa Health Insurance IPO, eligible investors can apply as Regular.